CLIENTS PARTICIPANTS

Research Updates From INQUIS

Interested in receiving our monthly Research Update?
Sign up here

How GLP-1 Medications are Influencing Consumer Health Behavior

How GLP-1 Medications are Influencing Consumer Health Behavior

GLP-1 (Glucagon-like Peptide-1) receptor agonists are rapidly reshaping the health and nutrition landscape. With

Read More
Meet with the INQUIS team this fall!

Meet with the INQUIS team this fall!

Our team is preparing for a busy fall season of clinical trials, conferences, trade

Read More
Behind the Trial: A Closer Look at Study Design  

Behind the Trial: A Closer Look at Study Design 

Trial design is one of the most important factors in generating meaningful data and

Read More
Highlights from 42nd International Symposium on Diabetes and Nutrition

Highlights from 42nd International Symposium on Diabetes and Nutrition

Our team thoroughly enjoyed the 42nd International Symposium on Diabetes and Nutrition, DNSG 2025.

Read More
New Science at ASN Nutrition 2025

New Science at ASN Nutrition 2025

We’ve returned from a whirlwind few days at ASN Nutrition 2025 in Orlando, full of

Read More
Hear Dr. Wolever speak about continuous glucose monitoring at DNSG

Hear Dr. Wolever speak about continuous glucose monitoring at DNSG

Will you be attending the 42nd International Symposium on Diabetes and Nutrition (DNSG 2025)

Read More
Spotlight on Tolerability Trials at INQUIS

Spotlight on Tolerability Trials at INQUIS

As the development of new sweeteners and fibers continues to grow, we’ve seen an

Read More
GLP-1 and the Food Industry: What We Know and Where We’re Going

GLP-1 and the Food Industry: What We Know and Where We’re Going

Fresh on the heels of the NutraIngredients Weight Management Summit, it’s time to check in

Read More
Celebrating 20 Years! Reflections from our Team: Atarah Grysman

Celebrating 20 Years! Reflections from our Team: Atarah Grysman

Read More
1 2 3 9
Contact Us Today
How can we help you achieve your research objectives?
  • This field is for validation purposes and should be left unchanged.